Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster of Differentiation Antigen 30 (CD30) Positive Peripheral TCell Lymphomas
Condition: T Cell Lymphoma Intervention: Drug: Brentuximab Vedotin Sponsors: Siddhartha Ganguly; Seattle Genetics, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials